Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering
Open Access
- 1 January 2016
- journal article
- review article
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 8 (1) , 10-14
Abstract
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose LoweringKeywords
This publication has 22 references indexed in Scilit:
- Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell FunctionThe Journal of Clinical Endocrinology & Metabolism, 2015
- Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label StudyDiabetes Therapy, 2014
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitorsJournal of the American Society of Hypertension, 2014
- Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor DapagliflozinDiabetes Technology & Therapeutics, 2014
- Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2013
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metforminDiabetes, Obesity and Metabolism, 2013
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal TubuleJournal of the American Society of Nephrology, 2011
- Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetesInternational Journal Of Clinical Practice, 2008
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998
- A Prospective Study of Maturity-Onset Diabetes Mellitus and Risk of Coronary Heart Disease and Stroke in WomenArchives of internal medicine (1960), 1991